<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02770625</url>
  </required_header>
  <id_info>
    <org_study_id>ISU302-004</org_study_id>
    <nct_id>NCT02770625</nct_id>
  </id_info>
  <brief_title>Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease</brief_title>
  <official_title>A Multicenter, Open-Label Phase III Study to Evaluate the Safety and Efficacy of ISU302 (Imiglucerase for Injection) in Patients With Type 1 Gaucher Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ISU Abxis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ISU Abxis Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of ISU302 in patients with
      Type 1 Gaucher disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this clinical study were to evaluate the efficacy and safety of every other
      week (EOW) dosing of ISU302 at a dose of 60 U/kg as an effective glucocerebrosidase enzyme
      replacement therapeutic product in patients with Type 1 Gaucher disease (GD). Primary
      efficacy endpoint was the difference in hemoglobin concentration between baseline and Week
      24. Secondary efficacy endpoints included assessment of platelet counts, spleen and liver
      volume, and biomarker levels in plasma at Week 24 compared to baseline; skeletal change and
      bone mineral density (BMD); and single-dose pharmacokinetic (PK) analysis. Secondary safety
      endpoints included the assessment of adverse events (AEs), vital signs, physical examination,
      and electrocardiogram (ECG); clinical safety laboratory analyses included serum chemistry,
      urinalysis, hematology and coagulation, and the measurement of anti-ISU302 antibodies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Difference in Hemoglobin Concentration [g/dL]</measure>
    <time_frame>from baseline to Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet Counts [10^3 Platelets/uL]</measure>
    <time_frame>from baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spleen Volume</measure>
    <time_frame>from baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Volume</measure>
    <time_frame>from baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiotensin-converting Enzyme Level</measure>
    <time_frame>from baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chitotriosidase Level (Nmol/mL/hr)</measure>
    <time_frame>from baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemokine Ligand (CCL-18) Level [ng/mL]</measure>
    <time_frame>from baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acid Phosphatase (ACP) Level (U/L)</measure>
    <time_frame>from baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal Status Improvement</measure>
    <time_frame>from baseline to Week 24</time_frame>
    <description>The number of participant who have the skeletal status diagnosed as Osteosclerosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bone Mineral Density</measure>
    <time_frame>from baseline to Week 24</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of AEs, Vital Signs, Physical Examination, and Electrocardiogram (ECG)</measure>
    <time_frame>Screening to Visit14 (Week 26)</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Gaucher Disease, Type 1</condition>
  <arm_group>
    <arm_group_label>ISU302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 U/kg (once every 2 weeks for 6 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISU302</intervention_name>
    <description>60 U/kg given intravenously</description>
    <arm_group_label>ISU302</arm_group_label>
    <other_name>Imiglucerase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Type 1 GD.

          -  Documented glucocerebrosidase deficiency.

          -  GD-related anemia, defined as hemoglobin levels of at least 1 g/dL below the lower
             limit of normal for age and gender and one or more of the following 3 criteria:

               -  At least moderate splenomegaly (2 to 3 cm below the left costal margin) by
                  palpation,

               -  GD-related thrombocytopenia, defined as a platelet count &lt;90 x 109 platelets/L,

               -  GD-related readily palpable enlarged liver.

          -  Not received treatment for GD (investigational products, miglustat, velaglucerase
             alfa, or imiglucerase) within 12 months prior to study entry.

          -  Ability to comprehend and willing to sign the ICF.

          -  Legal guardian (and patient if age appropriate) understood the nature of the
             procedure, was willing to comply with associated follow-up evaluations, and provided
             written informed consent and assent prior to the procedure.

          -  Female patients of childbearing potential must had agreed to use a medically
             acceptable method of contraception at all the times during the study. Male patients
             must have used a medically acceptable method of birth control throughout their
             participation in the study and were required to report the pregnancy of a partner.

        Exclusion Criteria:

          -  Type 2 or 3 GD.

          -  Splenectomy.

          -  Antibody positive to ISU302 or imiglucerase during screening or the patient had
             experienced an anaphylactic reaction to ISU302 or imiglucerase. - Treatment with any
             non-GD-related investigational drug or medical device within 30 days prior to study
             entry; such use during the study was also not permitted.

          -  Currently receiving red blood cell (RBC) growth factor (eg, erythropoietin) chronic
             systemic corticosteroids or received such treatment within the last 6 months.

          -  Positive for human immunodeficiency virus (HIV) and hepatitis B or C.

          -  Exacerbated anemia at screening (due to iron, folic acid, or vitamin B12 deficiency or
             infectious/immune-mediated cause).

          -  Significant comorbidity(ies) that could affect study data or confounded the study
             results (eg, malignancies, primary biliary cirrhosis, autoimmune liver disease).

          -  Pregnant or lactating female patients and those not willing to use highly effective
             barrier or medical method of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amel El Beshlawy, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abou El Reesh Children's Hospital</affiliation>
  </overall_official>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2016</study_first_posted>
  <results_first_submitted>February 10, 2017</results_first_submitted>
  <results_first_submitted_qc>June 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2017</results_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type I Gaucher</keyword>
  <keyword>ISU302</keyword>
  <keyword>Imiglucerase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 9 patients were planned to be enrolled in the study; 8 patients were enrolled into the study and all 8 patients completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ISU302</title>
          <description>60 U/kg (once every 2 weeks for 6 months)
ISU302: 60 U/kg given intravenously</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ISU302</title>
          <description>60 U/kg (once every 2 weeks for 6 months)
ISU302: 60 U/kg given intravenously</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8" spread="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>Kilogram per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.244" spread="1.9236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.9" spread="7.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100.40" spread="22.852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Difference in Hemoglobin Concentration [g/dL]</title>
        <time_frame>from baseline to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ISU302</title>
            <description>60 U/kg (once every 2 weeks for 6 months)
ISU302: 60 U/kg given intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>The Difference in Hemoglobin Concentration [g/dL]</title>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.49" spread="0.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 13 (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.44" spread="0.870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Counts [10^3 Platelets/uL]</title>
        <time_frame>from baseline to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ISU302</title>
            <description>60 U/kg (once every 2 weeks for 6 months)
ISU302: 60 U/kg given intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Counts [10^3 Platelets/uL]</title>
          <units>10^3 platelets/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.6" spread="72.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 13 (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.3" spread="47.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spleen Volume</title>
        <time_frame>from baseline to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ISU302</title>
            <description>60 U/kg (once every 2 weeks for 6 months)
ISU302: 60 U/kg given intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Spleen Volume</title>
          <units>Milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.047" spread="18.9140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 13 (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.207" spread="9.4730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Volume</title>
        <time_frame>from baseline to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ISU302</title>
            <description>60 U/kg (once every 2 weeks for 6 months)
ISU302: 60 U/kg given intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Volume</title>
          <units>Milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.530" spread="0.6078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.537" spread="0.5059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiotensin-converting Enzyme Level</title>
        <time_frame>from baseline to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ISU302</title>
            <description>60 U/kg (once every 2 weeks for 6 months)
ISU302: 60 U/kg given intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Angiotensin-converting Enzyme Level</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.71" spread="108.952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.31" spread="58.253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chitotriosidase Level (Nmol/mL/hr)</title>
        <time_frame>from baseline to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ISU302</title>
            <description>60 U/kg (once every 2 weeks for 6 months)
ISU302: 60 U/kg given intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Chitotriosidase Level (Nmol/mL/hr)</title>
          <units>nmol/mL/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11093.67" spread="10354.369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 13 (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3409.63" spread="3103.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chemokine Ligand (CCL-18) Level [ng/mL]</title>
        <time_frame>from baseline to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ISU302</title>
            <description>60 U/kg (once every 2 weeks for 6 months)
ISU302: 60 U/kg given intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Chemokine Ligand (CCL-18) Level [ng/mL]</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="927.05" spread="595.4552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="577.331" spread="310.0457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acid Phosphatase (ACP) Level (U/L)</title>
        <time_frame>from baseline to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ISU302</title>
            <description>60 U/kg (once every 2 weeks for 6 months)
ISU302: 60 U/kg given intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Acid Phosphatase (ACP) Level (U/L)</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.44" spread="7.517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.44" spread="4.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skeletal Status Improvement</title>
        <description>The number of participant who have the skeletal status diagnosed as Osteosclerosis</description>
        <time_frame>from baseline to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ISU302</title>
            <description>60 U/kg (once every 2 weeks for 6 months)
ISU302: 60 U/kg given intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Skeletal Status Improvement</title>
          <description>The number of participant who have the skeletal status diagnosed as Osteosclerosis</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bone Mineral Density</title>
        <time_frame>from baseline to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ISU302</title>
            <description>60 U/kg (once every 2 weeks for 6 months)
ISU302: 60 U/kg given intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bone Mineral Density</title>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.954" spread="1.5967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.104" spread="2.4558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Assessment of AEs, Vital Signs, Physical Examination, and Electrocardiogram (ECG)</title>
        <time_frame>Screening to Visit14 (Week 26)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years and 4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ISU302</title>
          <description>60 U/kg (once every 2 weeks for 6 months)
ISU302: 60 U/kg given intravenously</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ludwig angina</sub_title>
                <description>Ludwig angina / Infections and infestations</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>Bronchitis / Infections and infestations</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Viral pneumonia</sub_title>
                <description>Pneumonia viral / Infections and infestations</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Taekseung Kim</name_or_title>
      <organization>ISU ABXIS Co., Ltd.</organization>
      <phone>+82.31.696.4715</phone>
      <email>kimts@isu.co.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

